论文部分内容阅读
临床经验已证实β阻滞剂噻吗心安(timolol)具有降低眼压的作用,但也伴随着全身副作用。这些副作用包括支气管哮喘恶化、心动过缓、心功能不全。现用于眼科的卡替洛尔(carteolol)为非选择性β-受体阻滞剂,以其具有内在的拟交感神经活性(ISA)而有别于噻吗心安。这种特性是几种潜在的优点(包括不发生全身作用)有关。因此,对1％和2％卡替洛尔滴眼剂的临床功效和安全性与噻吗心安进行了多中心双盲比较评估。37个中心的研究者收集了患有原发性开角型青光眼或高眼压的334例病人。根据病人以前的
Clinical experience has shown that timolol, a beta blocker, has the effect of lowering IOP but is also accompanied by systemic side effects. These side effects include exacerbations of bronchial asthma, bradycardia, and cardiac insufficiency. Carteolol, now used in ophthalmology, is a nonselective β-blocker that is distinguished from timolol by its intrinsic sympathomimetic activity (ISA). This property is associated with several potential advantages, including the absence of systemic effects. Therefore, a multicenter, double-blind, comparative assessment of the clinical efficacy and safety of 1% and 2% carteolol eye drops versus timolol was performed. Thirty-seven center researchers collected 334 patients with primary open-angle glaucoma or ocular hypertension. According to the patient’s previous